DAFTAR PUSTAKA
1.
Knoll B, Lassmann B, Temesgen Z. Current Status of HIV infection : a review for non HIV-treating physicians. Int J of Dermatol 2007 ; 46 : 1219-28.
2.
UNAIDS. Global Report: UNAIDS report on the global AIDS epidemic2010. Geneva2010.
3.
Rasmaliah. "EPIDEMIOLOGI HIV/AIDS DAN UPAYA PENANGGULANGANNYA. 2011. from http://repository.usu.ac.id/bitstream/123456789/3771/1/fkmrasmaliah3.pdf.
4.
Murtiastutik D. Buku Ajar Infeksi Menular Seksual. Edisi 1. Surabaya : Airlangga University Press, 2008; 138 – 48.
5.
Nasronudin. HIV & AIDS Pendekatan Biologi Molekuler, Klinis dan Sosial. Edisi 1. Surabaya : Airlangga University Press. 2007; 11-13.
6.
Viviane D, Valeria Fink, Benita YIP, dkk. Association Between HIV-1 RNA Level and CD4 Cell Count Among Untreated HIV-Infected Individuals. American Public Health Association: Amerika. 2009
7.
Djoerban Z, Djauzi S. Penatalaksanaan Infeksi HIV di Pelayanan Kesehatan Dasar. In : Buku Ajar Ilmu Penyakit Dalam Edisi II. Editor : Aru W. Sudoyo, Bambang Setiyohadi, Idrus Alwi. Jakarta: Pusat Penerbitan FKUI. 2003; 1825 – 9.
76
8.
Arifin, Z. Acquired Immunodeficiency Syndrome (Infeksi HIV, AIDS). Unair. 2011; 17.
9.
O’Brien WA, Hartigan PH, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression. N Engl J Med 1996;334;426-341
10.
Ho DD, Moudgil T, Alam M. Quantitation of Human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321:1621-5
11.
Coombs RW, Collier AC, Allain JP, et al. Plasma viremia in Human immunodeficiency virus infection. N Engl J Med 1989;321:1621-5
12.
Piatak M, Saag MS, Yang LC, et al. High Levels of HIV-1 in Plasma during all stages of infection determined by competitive PCR. Science 1993;1749-54
13.
Linda Astari, S., Yunia Eka Safitri, Desy Hinda P (2009). "Viral load pada infeksi HIV." . Surabaya : Fakultas Kedokteran Universitas Airlangga. 2011; 26 (3): 557-67
14.
M Nesti, E Carlie, C Giaquinto, et al. "Correlation between viral load, plasma levels of CD4 - CD8 T lymphocytes and AIDS-related oral diseases: a multicentre study on 30 HIV+ children in the HAART era." J Biol Regul Homeost Agents. 2012; 26(3): 527-37.
15.
EJ Mills, C Bakanda, J Birungi, et al. "Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from
a large cohort in Uganda." . Official Journal Of The International AIDS Society. 2011; 25(6): 851-5. (Abstrak) 16.
M Perreau, AL Savoye, E De Crignis, et al. "Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production.". Official Journal Of The International AIDS Society. 2013; 210(1): 143-56.
17.
Sepkowitz KA. "AIDS--the first 20 years". N. Engl. J. Med. 2001; 344 (23): 1764–72
18.
CDC. Opportunistic Infection, CDC. 2003; 25: 150-5.
19.
Djoerban Z, Djauzi S. Infeksi HIV. In : Buku Ajar Ilmu Penyakit Dalam Edisi II. Editor : Aru W. Sudoyo, Bambang Setiyohadi, Idrus Alwi. Jakarta: Pusat Penerbitan FKUI; 2003; 1815 - 7
20.
Mandal, A. AIDS patofisiologi. 2010; 10 –3.
21.
DEPKES. Definisi pengertian virus HIV dan Penyakit AIDS. 2003
22.
CDC (1992). "1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults". CDC.
23.
DEPKES.
Laporan
Triwulan
Situasi
Perkembangan
HIV-AIDS
diIndonesia sampai dengan Maret 2012. 2012 24.
Divisions of HIV/AIDS Prevention (2003). "HIV and Its Transmission". Centers for Disease Control & Prevention.
25.
San Francisco AIDS Foundation (2006-04-14). "How HIV is spread".
26.
Lee, B. More on How HIV Causes AIDS, National Institute of Allergy and Infectious Diseases. 2004.
27.
Barre-Sinoussi F, Nugeyre M, Dauguet C, et al. Isolation of a TLympocytotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
28.
Gallo RC, Salahudin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patient with AIDS and at risk for AIDS. Science 1984;224:497-500
29.
Baratawidjaya, Karmen Garna. Imunologi Dasar. In : Buku Ajar Ilmu Penyakit Dalam Edisi ke-8. Editor : Aru W. Sudoyo, Bambang Setiyohadi, Idrus Alwi. FKUI: Jakarta, 2009; 56 - 63
30.
Preiser W. HIV Pathogenesis : What do the viruses do? http : //www.kgu.de/zhyg/virologie/virologie.html.
31.
Levy JA, Hoffman AD, Krames SM, et al. Isolation of Lympocytopathic retroviruses from San Fransisco patients with AIDS. Science 1984;25 – 840-2
32.
Clavel F, Guetard F, Brun-Veziner, et al. Isolation of a new human retrovirus from west african patients with AIDS in west africa. Science 1986;233:343-6.
33.
Nasronudin. Perjalanan Infeksi HIV. In : Pendekatan Biologi Molekuler, Klinis dan Sosial. Editor : Jusuf Barakbah, Eddy Soewandojo, Suharto, Usman Hadi, Wahyu Dwi Astuti. Surabaya : Airlangga Universty. 2007; 19 – 20.
34.
Nasronudin. Manifestasi Klinis. In : Pendekatan Biologi Molekuler, Klinis dan Sosial. Editor : Jusuf Barakbah, Eddy Soewandojo, Suharto, Usman Hadi, Wahyu Dwi Astuti. Surabaya : Airlangga Universty. 2007; 21-22.
35.
Runggu, C. "Informasi Dasar HIV/AIDS". 2011; from www.aids-ina.org.
36.
MENKES. Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antriretroviral pada Orang Dewasa dan Remaja. Kementrian Kesehatan RI: Jakarta, 2012.
37.
Mylonakis E, Paliou M, Rich JD. Plasma Viral load testing in the management of HIV Infection. Am Fam Physician 2001; 63: 483–90, 495 - 6.
38.
MJ Mugavero. "Viremia copy-years predicts mortality among treatmentnaïve
human
immunodeficiency
virus-infected
patients
initiating
antiretroviral therapy." Clinic Infection Diseases. 2011; 23: 451-3 39.
Mellors W John, Munoz Alvaro, Giorgi, et al. "Plasma Viral Load and CD4 Lymphocytes are prognostic markers of HIV - 1 infection". Official Journal Of The International AIDS Society. 1997; 126: 946 - 54.
40.
Holmes King K, Sparlking PF, Starnm WE, Piot P, Wasserheit JN, Corey L, et al. Transmission sexual of HIV. In : Sexually Transmitted Diseases 4th ed. Editor : Lippincott Williams & Wilkins. New York: McGraw-Hill; 2008; 212-5
41.
Felissa R. Lashley, Jerry D. Durham. The person with HIV/AIDS: nursing perspectives. Springer Publishing Company. 2009.
42.
K Sharrocks. "Missed opportunities for identifying primary HIV within genitourinary medical/HIV services." International Journal of STD and AIDS . 2012; 22: 540 – 3.
43.
DEPKES. HIV/AIDS. 1990
44.
G John, Bartlett. "Tes CD4." Medical Management of HIV Infection. 2005; 19 - 23.
45.
Centers for Disease Control and Prevention, HIV/AIDS Surveillance Report, vol. 21, Atlanta: U.S. Department of Health and Human Services, Centres
for
Disease
Control
and
Prevention,
2009,
http://www.cdc.gov.hiv/topics/surveilance/resources/reports/ index.htm. 46.
Centers for Disease C, Prevention, “Reported CD4+ Tlymphocyte and viral load results for adults and adolescents with HIV infection—37 states, 2005–2007,” HIV Surveillance Supplemental Report. 2010; 16 (1): 1 – 10.
47.
M. M. Kitahata, S. J. Gange, A. G. Abraham et al., “Effect of early versus deferred antiretroviral therapy for HIV on survival,” The New England Journal of Medicine. 2009; 360 (18): 1815 – 26.
48.
K. B. Ulett, J. H. Willig, H. Y. Lin et al., “The therapeutic implications of timely linkage and early retention inHIV care,” AIDS Patient Care and STDs. 2009; 23 (1): 41 – 9.
49.
S. M. Hammer, J. J. Eron Jr P, Reiss et al., “Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society-USA panel,” Journal of the American Medical Association. 2008; 300 (5): 555 – 70.
50.
J. V. Baker, G. Peng, J. Rapkin et al., “CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection,” AIDS. 2008; 22 (7): 841 – 8.
51.
WHO. National AIDS control programme. 2007.
52.
What is Viral Load. Available from: http://www.aids.org/factsheets/125viral-load-test.html.
53.
Centers for Disease Control and Prevention. Guidelines for laboratory test result reporting of human immunodeficiency virus type 1 ribonucleic acid determination. MMWR 2001; 50: 1–2.
54.
Schacker TW, Hughes JP, Shea T, et al. Biological an virological characteristics of primary HIV infection. Ann Intern Med. 1998 Apr 15; 128(8):613-20.
55.
Nasronudin. Derajat Berat Infeksi HIV dan AIDS. In : Pendekatan Biologi Molekuler, Klinis dan Sosial. Editor : Jusuf Barakbah, Eddy Soewandojo, Suharto, Usman Hadi, Wahyu Dwi Astuti. Surabaya : Airlangga Universty. 2007; 22 – 23.
56.
Philips AN, Eron JJ, Bartlett JA, et al. HIV RNA levels and the development of clinical disease. AIDS 1996; 10:859-65
57.
Broto R. Pengaruh penyakit infeksi terhadap status nutrisi sistem kekebalan tubuh manusia. Dexa Media. 2001;14:17-21
58.
Nasronudin. Upaya meningkatkan status imun pada infeksi HIV & AIDS melalui perbaikan nutrisi. In : Pendekatan Biologi Molekuler, Klinis dan
Sosial. Editor : Jusuf Barakbah, Eddy Soewandojo, Suharto, Usman Hadi, Wahyu Dwi Astuti. Surabaya : Airlangga Universty. 2007; 153–7. 59.
Cupler EJ. Acquired Immunodeficiency Syndrome. In : Neuroimmunology for the clinician. Editors: Rolak LA, Harati Y. Boston: Butterworth Heinemann. 1997; 393-418
60.
Schleifer SJ. Keller SE. Stressfull Event, Deppresive Disorders, and Immunity. In : Psychoneuroimmunology Interaction Between Brain, Nervus System, Behaviour, endocrine and Immune System. Editors : Schmoll HJ, Tewes U. Lewiston: Hogrefe & Huber Publishers. 1992; 91-9
61.
Andaru, G.S. Peranan faktor internal dan eksternal dalam pemilihan strategi
koping
stres
odha
dewasamuda.
Jakarta;
FKUI.
2005.
http//www.digilib.ui.ac.id 62.
Nasronudin. HIV , stres dan stresor. In : Pendekatan Biologi Molekuler, Klinis dan Sosial. Editor : Jusuf Barakbah, Eddy Soewandojo, Suharto, Usman Hadi, Wahyu Dwi Astuti. Surabaya : Airlangga Universty. 2007; 161-7.
63.
French RF, Stewart GJ, Penny R, levy JA. How HIV produces immune deficiency. In : Stewart GJ editor. Managing HIV. Sydney : Australian Medical publishing Co. Limited, 1997; 22-8
64.
Luster AD. Chemokines-Chemotactic Cytokines that mediate inflamation. N Eng J Med 2000;338:436-45.
65.
Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344:720–5.
66.
Hubert JB RC, Boufassa F, Delfraissy JF, Meyer L. Gender, disease progression and response to HAART. Int Conf AIDS. 2002.
67.
Touloumi G, Pantazis N, Babiker AG, et al. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS 2004; 18:1697–705.
68.
Babiker AG, Peto T, Porter K, Walker AS, Darbyshire JH. Age as a determinant of survival in HIV infection. J Clin Epidemiol. 2001; 54: 16 – 21.
69.
Collaborative Group on AIDS Incubation and HIV Survival. Time from HIV-1 seroconversion to AIDS and death before widespread use of highlyactive anti-retroviral therapy. A collaborative analysis. Lancet 2000; 355: 1131-7.
70.
Lindau ST, Schumm LP, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 357: 762 – 74.
71.
WHO.The unexplored story of HIV and ageing.2009. Available from : http://www.who.int/bulletin/volumes/87/3/09-064030/en/
72.
Beyer M, Gerlach FM, Flies U, Grol R. The development of quality circles/peer review groups as a method of quality improvement in Europe. Family Practice 2003;20(4):443-51.
73.
UNAIDS.
Epidemic
update.
2006.
Available
from
:
http://data.unaids.org/pub/epireport/2006/2006_epiupdate_en.pdf. 74.
Simard EP et al. The influence of sex, race.ethnicity and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007, Arch Intern Med, online edition, 2012.
75.
Amie L, Meditz et al. Sex, Race, and Geographic Region InfluenceClinical Outcomes Following Primary HIV-1Infection. Oxford University Press on behalf of the InfectiousDiseases Society of America. 2011.
76.
Cohen, S., dan Syme, L. S. Social Support and Health. London : Academic Press. Inc. 1985.
77.
Nasronudin. Respons Aksis Hypothalamic-Pituitary-Adrenal terhadap infeksi HIV&AIDS Peran Dukungan Psikososial dan Pengobatan Antiretroviral. In : Pendekatan Biologi Molekuler, Klinis dan Sosial. Editor : Jusuf Barakbah, Eddy Soewandojo, Suharto, Usman Hadi, Wahyu Dwi Astuti. Surabaya : Airlangga Universty. 2007; 169-175.
78.
Carter Michael. Hubungan Erat Antara Peningkatan Viral Load dan Penurunan CD4 pada Pasien yang Tidak Menggunakan Terapi HIV. 2010
79.
A. O, Pasternak. Viral Load Meningkat Dalam Sel Memprediksi Penurunan CD4 pada Pasien Tanpa Gejala. 2010
80.
Andi Sompa Weri, Cahyono Kaelan, Yudy Gaysal. Hubungan Jumlah CD4 dengan Derajat Dystal Symmetrical Polyneuropathy (DSP) pada Penderita HIV / AIDS.UNHAS. 2012
81.
Le Tuan, J. Edwina, M. Davery, et. Al. Enhanced CD4+ T-Cell Recovery with Earlier HIV – 1 Antiretroviral Theraphy. N Eng J med. 2013 ; 368 : 218 – 30.
Lampiran 1. CASE REPORT FORM
65
Lampiran 2. ETHICAL CLEARANCE
Lampiran 3. Surat Ijin Pengambilan Data Penelitian
Lampiran 4. Hasil Analisis SPSS
FREQUENCIES VIRAL LOAD Statistics VIRAL LOAD N
Valid
86
Missing
0
Mean
1,69
Std. Error of Mean
,050
Median
2,00
Mode
2
Std. Deviation
,467
Variance
,218
Range
1
Minimum
1
Maximum
2 VIRAL LOAD
Frequency Valid
Percent
Valid Percent
Cumulative Percent
TERDETEKSI
27
31,4
31,4
31,4
TAK TERDETEKSI
59
68,6
68,6
100,0
Total
86
100,0
100,0
FREQUENCIES JUMLAH CD4 Statistics JUMLAH CD4 N
Valid Missing
86 0
Mean
1,47
Std. Error of Mean
,054
Median
1,00
Mode
1
Std. Deviation
,502
Variance
,252
Range
1
Minimum
1
Maximum
2
JUMLAH CD4
Frequency Valid
KURANG DARI SAMA DENGAN 200
46
LEBIH DARI 200
40
Total
86
Percent
Cumulative Percent
Valid Percent
53,5
53,5
53,5
46,5
46,5
100,0
100,0
100,0
CROSSTABS Case Processing Summary Cases Valid N VIRAL LOAD * JUMLAH CD4
Missing Percent
86
N
100,0%
Total
Percent 0
N
,0%
Percent 86
100,0%
VIRAL LOAD * JUMLAH CD4 Crosstabulation
JUMLAH CD4 KURANG DARI SAMA LEBIH DENGAN 200 DARI 200 VIRAL LOAD
TERDETEKSI
Count Expected Count
TAK TERDETEKSI
9
27
14,4
12,6
27,0
% within VIRAL LOAD
66,7%
33,3%
100,0%
% within JUMLAH CD4
39,1%
22,5%
31,4%
% of Total
20,9%
10,5%
31,4%
Count
28
31
59
31,6
27,4
59,0
% within VIRAL LOAD
47,5%
52,5%
100,0%
% within JUMLAH CD4
60,9%
77,5%
68,6%
% of Total
32,6%
36,0%
68,6%
Expected Count
Total
18
Total
Count
46
40
86
46,0
40,0
86,0
% within VIRAL LOAD
53,5%
46,5%
100,0%
% within JUMLAH CD4
100,0%
100,0%
100,0%
53,5%
46,5%
100,0%
Expected Count
% of Total
Chi-Square Tests
Pearson Chi-Square Continuity Correction(a) Likelihood Ratio
1
Asymp. Sig. (2-sided) ,097
2,029
1
,154
2,792
1
,095
Value 2,747(b)
df
Fisher's Exact Test
Exact Sig. (2-sided)
Exact Sig. (1-sided)
,110
Linear-by-Linear Association
2,715
N of Valid Cases
86
1
,099
a Computed only for a 2x2 table b 0 cells (,0%) have expected count less than 5. The minimum expected count is 12,56.
Risk Estimate
Value
95% Confidence Interval
Lower
Upper
Lower
Odds Ratio for VIRAL LOAD (TERDETEKSI / TAK TERDETEKSI)
2,214
,857
5,722
For cohort JUMLAH CD4 = KURANG DARI SAMA DENGAN 200
1,405
,962
2,051
For cohort JUMLAH CD4 = LEBIH DARI 200
,634
,353
1,140
N of Valid Cases
86
,077
CROSSTABS Case Processing Summary Cases Valid N VIRAL LOAD TERDETEKSI MENINGGAL ATAU TIDAK MENINGGAL * JUMLAH CD4
Missing Percent
27
31,4%
N
Total
Percent
59
N
68,6%
Percent
86
100,0%
VIRAL LOAD TERDETEKSI MENINGGAL ATAU TIDAK MENINGGAL * JUMLAH CD4 Crosstabulation
JUMLAH CD4 KURANG DARI SAMA LEBIH DENGAN 200 DARI 200 VIRAL LOAD TERDETEKSI MENINGGAL ATAU TIDAK MENINGGAL
MENINGGAL
TIDAK MENINGGAL
Total
Count
Total
8
1
9
% within VIRAL LOAD TERDETEKSI MENINGGAL ATAU TIDAK MENINGGAL
88,9%
11,1%
100,0%
% within JUMLAH CD4
44,4%
11,1%
33,3%
% of Total
29,6%
3,7%
33,3%
10
8
18
% within VIRAL LOAD TERDETEKSI MENINGGAL ATAU TIDAK MENINGGAL
55,6%
44,4%
100,0%
% within JUMLAH CD4
55,6%
88,9%
66,7%
% of Total
37,0%
29,6%
66,7%
Count
Count
18
9
27
% within VIRAL LOAD TERDETEKSI MENINGGAL ATAU TIDAK MENINGGAL
66,7%
33,3%
100,0%
% within JUMLAH CD4
100,0%
100,0%
100,0%
66,7%
33,3%
100,0%
% of Total
CROSSTABS Case Processing Summary Cases Valid N VIRAL LOAD TAK TERDETEKSI MENINGGAL ATAU TIDAK * JUMLAH CD4
Missing Percent
59
68,6%
N
Total
Percent
27
N
31,4%
Percent
86
100,0%
VIRAL LOAD TAK TERDETEKSI MENINGGAL ATAU TIDAK * JUMLAH CD4 Crosstabulation
VIRAL LOAD TAK TERDETEKSI MENINGGAL ATAU TIDAK
MENINGGAL
Count Expected Count
TIDAK MENINGGAL
Total
12
5,7
6,3
12,0
% within VIRAL LOAD TAK TERDETEKSI MENINGGAL ATAU TIDAK
75,0%
25,0%
100,0%
% within JUMLAH CD4
32,1%
9,7%
20,3%
% of Total
15,3%
5,1%
20,3%
19
28
47
Count Expected Count
Total
JUMLAH CD4 KURANG DARI SAMA LEBIH DENGAN 200 DARI 200 9 3
22,3
24,7
47,0
% within VIRAL LOAD TAK TERDETEKSI MENINGGAL ATAU TIDAK
40,4%
59,6%
100,0%
% within JUMLAH CD4
67,9%
90,3%
79,7%
% of Total
32,2%
47,5%
79,7%
28
31
59
28,0
31,0
59,0
47,5%
52,5%
100,0%
100,0%
100,0%
100,0%
47,5%
52,5%
100,0%
Count Expected Count % within VIRAL LOAD TAK TERDETEKSI MENINGGAL ATAU TIDAK % within JUMLAH CD4 % of Total
CROSSTABS Case Processing Summary Cases Valid N STADIUM KLINIS PASIEN * VIRAL LOAD
Missing Percent
86
100,0%
N
Total
Percent 0
,0%
N
Percent 86
100,0%
STADIUM KLINIS PASIEN * VIRAL LOAD Crosstabulation
STADIUM KLINIS PASIEN
RINGAN
Count Expected Count
12
3,8
8,2
12,0
41,7%
58,3%
100,0%
% within VIRAL LOAD
18,5%
11,9%
14,0%
5,8%
8,1%
14,0%
22
52
74
23,2
50,8
74,0
% within STADIUM KLINIS PASIEN
29,7%
70,3%
100,0%
% within VIRAL LOAD
81,5%
88,1%
86,0%
% of Total
25,6%
60,5%
86,0%
27
59
86
27,0
59,0
86,0
31,4%
68,6%
100,0%
100,0%
100,0%
100,0%
31,4%
68,6%
100,0%
Count Expected Count
Total
Total
% within STADIUM KLINIS PASIEN % of Total BERAT
VIRAL LOAD TAK TERDETEKSI TERDETEKSI 5 7
Count Expected Count % within STADIUM KLINIS PASIEN % within VIRAL LOAD % of Total
Chi-Square Tests
Pearson Chi-Square Continuity Correction(a) Likelihood Ratio
1
Asymp. Sig. (2-sided) ,409
,241
1
,623
,656
1
,418
Value ,683(b)
df
Fisher's Exact Test
Exact Sig. (2-sided)
Exact Sig. (1-sided)
,505
Linear-by-Linear Association
,675
N of Valid Cases
86
1
,411
a Computed only for a 2x2 table b 1 cells (25,0%) have expected count less than 5. The minimum expected count is 3,77. Risk Estimate
Value
95% Confidence Interval
Lower
Upper
Lower
Odds Ratio for STADIUM KLINIS PASIEN (RINGAN / BERAT)
1,688
,483
5,900
For cohort VIRAL LOAD = TERDETEKSI
1,402
,658
2,984
For cohort VIRAL LOAD = TAK TERDETEKSI
,830
,503
1,369
N of Valid Cases
86
,304
CROSSTABS Case Processing Summary Cases Valid N STADIUM KLINIS PASIEN * JUMLAH CD4
Missing Percent
86
100,0%
N
Total
Percent 0
N
,0%
Percent 86
100,0%
STADIUM KLINIS PASIEN * JUMLAH CD4 Crosstabulation
STADIUM KLINIS PASIEN
RINGAN
Count Expected Count
12
5,6
12,0
16,7%
83,3%
100,0%
% within JUMLAH CD4
4,3%
25,0%
14,0%
% of Total
2,3%
11,6%
14,0%
Count
44
30
74
39,6
34,4
74,0
% within STADIUM KLINIS PASIEN
59,5%
40,5%
100,0%
% within JUMLAH CD4
95,7%
75,0%
86,0%
% of Total
51,2%
34,9%
86,0%
Expected Count
Total
Total
6,4
% within STADIUM KLINIS PASIEN
BERAT
JUMLAH CD4 KURANG DARI SAMA LEBIH DENGAN 200 DARI 200 2 10
Count Expected Count % within STADIUM KLINIS PASIEN % within JUMLAH CD4 % of Total
46
40
86
46,0
40,0
86,0
53,5%
46,5%
100,0%
100,0%
100,0%
100,0%
53,5%
46,5%
100,0%
Directional Measures
Value Nominal by Nominal
Lambda
Goodman and Kruskal tau
a b c d
Asymp. Std. Error(a)
Approx. T(b)
Approx. Sig.
Symmetric
,154
,055
2,385
,017
STADIUM KLINIS PASIEN Dependent
,000
,000
.(c)
.(c)
JUMLAH CD4 Dependent
,200
,077
2,385
,017
,088
,054
,006(d)
,088
,051
,006(d)
STADIUM KLINIS PASIEN Dependent JUMLAH CD4 Dependent
Not assuming the null hypothesis. Using the asymptotic standard error assuming the null hypothesis. Cannot be computed because the asymptotic standard error equals zero. Based on chi-square approximation
Lampiran 5. Identitas Mahasiswa IDENTITAS Nama
: Elizabeth Fajar Puteri Pertiwi
NIM
: G2A009163
Tempat / Tanggal lahir
: Banjarmasin, 27 Juni 1991
Jenis Kelamin
: Perempuan
Alamat
: Perum Kutoharjo, Pati.
Nomor telepon
: (0295) 394246
Nomor HP
: 085640959527
Email
: Elizabeth
[email protected]
RIWAYAT PENDIDIKAN FORMAL 1. SD
: SD Pati Kidul 01 Pati
Lulus Tahun : 2003
2. SMP
: SMP 2 Pati
Lulus Tahun : 2006
3. SMA
: SMA 1 Pati
Lulus Tahun : 2009
4. FK UNDIP : Masuk tahun 2009 KEANGGOTAAN ORGANISASI 1. BEM FK UNDIP Ekonomi Keuangan dan Investasi Tahun 2009 s/d 2011 2. PENGURUS PMKK FK UNDIP Tahun 2012 s/d 2013.
